Life sciences company Avacta Therapeutics has announced the appointment of Brian Hahn as its new chief financial officer (CFO).

Hahn has more than 25 years of senior financial and operations experience in the biopharmaceutical industry, including a 15-year tenure as CFO and senior vice president of GlycoMimetics, Inc.

Prior to his 15-year tenure at GlycoMimetics, Hahn held roles of increasing financial leadership responsibility, including executive director of finance at MiddleBrook Pharmaceuticals, and earlier, senior accountant with Bering Truck Corporation.

Hahn commented: “What drew me to Avacta was not just the company’s innovative technology platforms. It also has a clear vision for revolutionizing cancer treatment through targeted therapies that improve outcomes for patients and their families.

“I look forward to leveraging my experience to help accelerate Avacta’s growth and strengthen its position in both the UK and US capital markets.”

Avacta CEO, Christina Coughlin, added: “Brian brings the ideal combination of deep public company experience and understanding of the biotechnology sector that Avacta needs at this transformative stage.

“His strategic insight and track record of successful financial leadership in clinical-stage companies will be essential as we advance our promising pipeline and prepare for our next phase of growth, including our potential dual listing on the Nasdaq exchange.”

---